scholarly journals Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell linesin vitro

Hepatology ◽  
2013 ◽  
Vol 57 (5) ◽  
pp. 1838-1846 ◽  
Author(s):  
Richard S. Finn ◽  
Alexey Aleshin ◽  
Judy Dering ◽  
Peter Yang ◽  
Charles Ginther ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Small Molecule ◽  
Kinase Inhibitor ◽  
Carcinoma Cell ◽  
Molecular Subtype ◽  
Small Molecule Kinase Inhibitor ◽  
Hepatocellular Carcinoma Cell

scholarly journals Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death

2009 ◽  
Vol 8 (8) ◽  
pp. 2183-2192 ◽  
Author(s):  
Justin R. Pritchard ◽  
Benjamin D. Cosgrove ◽  
Michael T. Hemann ◽  
Linda G. Griffith ◽  
Jack R. Wands ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Death ◽  
Kinase Inhibitor ◽  
Carcinoma Cell ◽  
Hepatocellular Carcinoma Cell ◽  
Inhibitor Combination

scholarly journals Ponatinib Inhibits Proliferation and Induces Apoptosis of Liver Cancer Cells, but Its Efficacy Is Compromised by Its Activation on PDK1/Akt/mTOR Signaling

Molecules ◽  
2019 ◽  
Vol 24 (7) ◽  
pp. 1363 ◽  
Author(s):  
Chang Liu ◽  
Xiuli Mu ◽  
Xuan Wang ◽  
Chan Zhang ◽  
Lina Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Proliferation ◽  
Protein Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Carcinoma Cell ◽  
Mtor Signaling ◽  
Cancer Drug ◽  
Negative Effects ◽  
Stat3 Phosphorylation ◽  
Hepatocellular Carcinoma Cell

Ponatinib is a multi-target protein tyrosine kinase inhibitor, and its effects on hepatocellular carcinoma cells have not been previously explored. In the present study, we investigated its effects on hepatocellular carcinoma cell growth and the underlying mechanisms. Toward SK-Hep-1 and SNU-423 cells, ponatinib induces apoptosis by upregulation of cleaved caspase-3 and -7 and promotes cell cycle arrest in the G1 phase by inhibiting CDK4/6/CyclinD1 complex and phosphorylation of retinoblastoma protein. It inhibits the growth-stimulating mitogen-activated protein (MAP) kinase pathway, the phosphorylation of Src on both negative and positive regulation sites, and Jak2 and Stat3 phosphorylation. Surprisingly, it also activates the PDK1, the protein kinase B (Akt), and the mechanistic target of rapamycin (mTOR) signaling pathway. Blocking mTOR signaling strongly sensitizes cells to inhibition by ponatinib and makes ponatinib a much more potent inhibitor of hepatocellular carcinoma cell proliferation. These findings demonstrate that ponatinib exerts both positive and negative effects on hepatocellular cell proliferation, and eliminating its growth-stimulating effects by drug combination or potentially by chemical medication can significantly improve its efficacy as an anti-cancer drug.

The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415

2017 ◽  
Vol 487 (3) ◽  
pp. 494-499 ◽  
Author(s):  
Wei Zhang ◽  
Bingyu Chen ◽  
Yu Zhang ◽  
Kaiqiang Li ◽  
Ke Hao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Kinase Inhibitor ◽  
Carcinoma Cell ◽  
Cell Activity ◽  
Mtor Kinase ◽  
Hepatocellular Carcinoma Cell

SYNTHESIS AND CYTOTOXICITY OF POLYHYDROXYLATED CHOLESTEROL DERIVATIVES

2018 ◽  
Vol 56 (4) ◽  
pp. 467
Author(s):  
Thu Thuy Thi Tran ◽  
Ha Thi Dinh ◽  
Phương Lan Doan ◽  
Long Quoc Pham ◽  
Quang Dai Ngo
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Line ◽  
Cell Lines ◽  
Carcinoma Cell ◽  
Addition Compound ◽  
Hep G2 ◽  
Physical Methods ◽  
Hepatocellular Carcinoma Cell Line ◽  
Human Hepatocellular Carcinoma Cell ◽  
Hepatocellular Carcinoma Cell

Eight polyhydroxylated cholesterol derivatives (1-8) were prepared from cholesterol, using oxidative reagents as SeO2, OsO4/NMO, HCOOH/H2O2 and BH3/ H2O2. Their structures were elucidated by using physical methods including NMR 1D and 2D. These compounds were evaluated against two cancer cell lines (Hep-G2, T98). Compounds 2, 4 and 8 inhibits human hepatocellular carcinoma cell line (Hep-G2) with IC50 4.69, 4.98 and 2.89 µg/mL, respectively. In addition, compound 8 exhibited strong cytotoxicity against T98 cell line (glioblastoma) with IC50 = 2.28 μM.

Role of GSK-3β in hepatocellular carcinoma cell migration

2010 ◽  
Vol 30 (1) ◽  
pp. 28-32
Author(s):  
Jian-fei WANG ◽  
Ying HOU ◽  
Rui-liang GE ◽  
Yi-zheng WANG ◽  
Feng SHEN ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Migration ◽  
Carcinoma Cell ◽  
Hepatocellular Carcinoma Cell ◽  
Gsk 3Β
Sign in / Sign up

Export Citation Format

Share Document